Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001924962 | SCV002153600 | uncertain significance | not provided | 2022-08-12 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 520 of the SLC34A1 protein (p.Leu520Pro). This variant is present in population databases (rs201728701, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with SLC34A1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1384994). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002482662 | SCV002790531 | uncertain significance | Hypophosphatemic nephrolithiasis/osteoporosis 1; Fanconi renotubular syndrome 2; Hypercalcemia, infantile, 2 | 2022-01-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003289171 | SCV003956616 | uncertain significance | Inborn genetic diseases | 2023-04-14 | criteria provided, single submitter | clinical testing | The c.1559T>C (p.L520P) alteration is located in exon 13 (coding exon 12) of the SLC34A1 gene. This alteration results from a T to C substitution at nucleotide position 1559, causing the leucine (L) at amino acid position 520 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |